2022: The State of Sunscreen in the U.S.
…in Melanoma Research, Professor & Chair, Department of Dermatology, Oregon Health & Science University. Over 197,000 cases of melanoma are…
2022: The State of Sunscreen in the U.S.
…in Melanoma Research, Professor & Chair, Department of Dermatology, Oregon Health & Science University. Over 197,000 cases of melanoma are…
Survivor Spotlight: Erich & Jenn Djordjevic
…heard about the lesions, Jenn’s mind flashed to 2013, when Erich was diagnosed with Stage IIIB melanoma. He had a…
,
AIM Welcomes Ann Garst Taylor as New Director of Community Engagement
By Mara Klecker Ann Garst Taylor, AIM at Melanoma’s new Director of Community Engagement, has nearly 30 years of volunteer…
,
Things Are About To Get Hairy!
…at Melanoma is proud to have been selected as a 2022 benefitting charity. The “rules” are as simple. You abstain…
How’s it Growing?
AIM at Melanoma is honored to have been selected by the Matthew Hill Foundation to be a benefitting charity in…
,
Shop the Black Ribbon Boutique in May
Since 2020, AIM at Melanoma has partnered with Bonfire.com to sell t-shirts that raise awareness of melanoma as well as…
,
AIM’s Latest Newsletter: The Research Edition, July 2023
This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
,
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
…clinical study. January 17, 2024 – original article in Targeted Oncology Sabrina Serani DermaSensor provides quantitative, point-of-testing identification for…
,
,
Secure Your Legacy With a Click
Ways to Give: Estate Gifts First Article in a Series Here at AIM at Melanoma, we are fortunate to be…
,
April 2025 Newsletter
This month, we delve into one of the most groundbreaking developments in melanoma research: vaccines. Our spotlight article examines the potential of mRNA…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026